ArticleImmunologic research2017
Analysis of FOXP3
Article in Immunologic research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Immunopathogenesis of neuropsychiatric systemic lupus erythematosus: current insights into inflammatory and thrombotic pathways.Journal of neuroinflammation · 2026Review
- miR-452-5p promotes systemic lupus erythematosus-induced inflammatory responses by downregulating RBL2 and impairing Treg development.Immunologic research · 2026Article
- Initial or continuous coculture with umbilical cord-derived mesenchymal stromal cells facilitates in vitro expansion of human regulatory T-cell subpopulations.Stem cells translational medicine · 2025Article
- Low-dose interleukin-2 therapy in systemic lupus erythematosus.Rheumatology and immunology research · 2023Review
- Skin infiltrating T-cell profile of drug reaction with eosinophilia and systemic symptoms (DRESS) reactions among HIV-infected patients.Frontiers in medicine · 2023Article
- Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders - Advances and challenges.Human vaccines & immunotherapeutics · 2022Review
- Downregulation of TIGIT Expression in FOXP3+Regulatory T Cells in Acute Coronary Syndrome.Journal of inflammation research · 2022Article
- The emerging role of regulatory cell-based therapy in autoimmune disease.Frontiers in immunology · 2022Review
- New biomarkers in SLE: from bench to bedside.Rheumatology (Oxford, England) · 2020Review
- Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.Frontiers in immunology · 2018Review
- CCR6PeerJ · 2018Article
- Modulation of the Immune System for the Treatment of Glaucoma.Current neuropharmacology · 2018Review
- Editorial: Cutting edge in systemic lupus erythematosus.Immunologic research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) are critical mediators of immune tolerance, yet their involvement in the autoimmune disease systemic lupus erythematosus (SLE) is incompletely understood. We analyzed CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.